A phase ii trial of short course fludarabine, mitoxantrone, rituximab followed by 90y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma

Annals of Oncology

Volumn 23, Issue 2, 2012, Pages 415-420

  Zinzani, P L ^a   Tani, M ^a   Pulsoni, A ^b   De Renzo, A ^c   Stefoni, V ^a   Broccoli, A ^a   Montini, G C ^a   Fina, M ^a   Pellegrini, C ^a   Gandolfi, L ^a   Cavalieri, E ^b   Torelli, F ^b   Scopinaro, F ^b   Argnani, L ^a   Quirini, F ^a   Derenzini, E ^a   Rossi, M ^a   Pileri, S ^a   Fanti, S ^a   Baccarani, M ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Fludarabine; Follicular lymphoma; Mitoxantrone; Radioimmunotherapy; Rituximab

Indexed keywords

FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IBRITUMOMAB TIUXETAN; METHOTREXATE; RITUXIMAB;

ADULT; AGED; ANEMIA; ARTICLE; BONE MARROW; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CELL INFILTRATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; FOLLICULAR LYMPHOMA; GRANULOCYTE; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RADIOIMMUNOTHERAPY; SHORT COURSE THERAPY; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT RESPONSE;

EID: 84856320007     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr145     Document Type: Article

References (30)

1. Jones SE, Grozea PN, Metz EN et al. Improved complete remission rates and survival for patients with large cell lymphoma treated with chemoimmunotherapy. A Southwest Oncology Group Study. Cancer 1983; 51: 1083-1090.
2. Hagenbeek A, Eghbali H, Monfardini S et al. Phase III intergroup study of fludarabine phosphate compared with cyclophosphamide, vincristine, and prednisone chemotherapy in newly diagnosed patients with stage III and IV lowgrade malignant Non-Hodgkin's lymphoma. J Clin Oncol 2006; 24(10): 1590-1596.
3. Czuczman MS, Grillo-Ló pez AJ, White CA et al. Treatment of patients with lowgrade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999; 17: 268-276.
4. Marcus R, Imrie K, Solal-Celigny P et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 2008; 26: 4579-4586.
5. Hiddemann W, Kneba M, Dreyling M et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005; 106: 3725-3732.
6. Herold M, Haas A, Srock S et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol 2007; 25: 1986-1992.
7. Anderson KC, Bates MP, Slaughenhoupt BL et al. Expression of human B cellassociated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood 1984; 63: 1424-1433.
8. Witzig TE, White CA, Wiseman GA et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol 1999; 17: 3793-3803.
9. Witzig TE, Gordon LI, Cabanillas F et al. Randomized controlled trial of Yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002; 20: 2453-2463.
10. Witzig TE, Flinn IF, Gordon LI et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 2002; 20: 3262-3269.
11. Tobinai K, Watanabe T, Ogura M et al. Japanese phase II study of 90Yibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma. Cancer Sci 2009; 100: 158-164.
12. Leonard JP, Coleman M, Kostakoglu L et al. Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma. J Clin Oncol 2005; 23: 5696-5704.
13. Zinzani PL, Tani M, Pulsoni A et al. Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ). Lancet Oncol 2008; 9: 352-358.
14. Press OW, Unger JM, Braziel RM et al. Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Group protocol S9911. J Clin Oncol 2006; 24: 4143-4149.
15. Morschhauser F, Radford J, Van Hoof A et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 2008; 26: 5156-5164.
16. Jacobs SA, Swerdlow SH, Kant J et al. Phase II trial of short-course CHOP-R followed by 90Y-ibritumomab tiuxetan and extended rituximab in previously untreated follicular lymphoma. Clin Cancer Res 2008; 14: 7088-7094.
17. Hainsworth JD, Spigel DR, Markus TM et al. Rituximab plus short-duration chemotherapy followed by yttrium-90 ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: a phase II trial of the Sarah Cannon Oncology Research Consortium. Clin Lymphoma Myeloma 2009; 9: 223-228.
18. McLaughlin P, Neelapu S, Fanale M et al. R-FND followed by radioimmunotherapy fpor high-risk follicular lymphoma. Blood 2008; 112: 3056a.
19. Solal-Celigny P, Roy P, Colombat P et al. Follicular lymphoma international prognostic index. Blood 2004; 104: 1258-1265.
20. Harris NL, Jaffe ES, Diebold J et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17: 3835-3849.
21. Cheson BD, Pfistner B, Juweid ME et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25(5): 579-586.
22. A'Hern RP. Sample size tables for exact single-stage phase II designs. Stat Med 2001; 20: 859-866.
23. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
24. Zinzani PL, Pulsoni A, Perrotti A et al. Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma. J Clin Oncol 2004; 22: 2654-2661.
25. Salles G, Mounier N, de Guibert S et al. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELMAS FL2000 study. Blood 2008; 112: 4824-4831.
26. Zinzani PL, Lauria F, Rondelli D et al. Fludarabine: an active agent in the treatment of previously-treated and untreated low-grade non-Hodgkin's lymphoma. Ann Oncol 1993; 4: 575-578.
27. McLaughlin P, Hagemeister FB, Swan F et al. Phase I study of the combination of fludarabine, mitoxantrone, and dexamethasone in low-grade lymphoma. J Clin Oncol 1994; 12: 575-579.
28. Zinzani PL, Bendandi M, Magagnoli M et al. Fludarabine-mitoxantrone combination-containing regimen in recurrent low-grade non-Hodgkin's lymphoma. Ann Oncol 1997; 8: 379-383.
29. Rambaldi A, Lazzari M, Manzoni C et al. Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma. Blood 2002; 99: 856-862.
30. Kaminski MS, Tuck M, Estes J et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 2005; 352: 441-449.